Abstract
This report summarizes the clinical features and the indications for treating HCV
infection in immunocompromised and transplanted patients in the Direct Acting Antiviral
drugs era.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sistema Nazionale per le Linee Guida Manuale metodologico.Zadig, Milano2013
Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook. https://gdt.gradepro.org/app/handbook/handbook.html.
- Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol. 2005; 5: 215-229
- Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.J Clin Invest. 1996; 98: 706-714
- HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).Gastroenterology. 2007; 133: 1132-1143
- Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.Liver Int. 2016; 36: 1585-1589
- Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.J Hepatol. 2012; 57: 1177-1185
- Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy.Gut Liver. 2017; 11: 870-877
- Effects of chronic hepatitis C infection on the treatment of breast cancer patients.Ann Oncol. 2010; 21: 1233-1236
- Hepatitis B reactivation during or after direct acting antiviral therapy — implication for susceptible individuals.Expert Opin Drug Saf. 2017; 16: 651-672
- Persistent LCMV infection is controlled by blockade of type I interferon signaling.Science. 2013; 340: 207-211
- Global epidemiology and genotype distribution of the hepatitis C virus infection.J Hepatol. 2014; 61: S45-S57
- Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy.New Microbiol. 2018; 41: 26-29
- HCV — estimation of the number of diagnosed patients eligible to the new anti-HCV therapies in Italy.Eur Rev Med Pharmacol Sci. 2016; 20: S7-S10
- Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population-based survey.Eur J Int Med. 2018; 53: 79-84
- Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: tail of a cohort infected in past decades.J Med Virol. 2017; 89: 291-297
- The long and winding road leading to the identification of the hepatitis C virus.J Hepatol. 2009; 51: 939-948
- Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122.J Virol. 2012; 86: 1382-1393
- The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.J Hepatol. 2016; 65: S2-S21
- Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.Blood. 2010; 116: 5119-5125
- Immune response to HCV and other hepatitis viruses.Immunity. 2014; 40: 13-24
- Binding of hepatitis C virus to CD81.Science. 1998; 282: 938-941
- Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.J Hepatol. 2017; 66: 1282-1299
- Hepatitis C Virus lipoviroparticles assemble in the endoplasmic reticulum (ER) and bud off from the ER to the Golgi compartment in COPII vesicles.J Virol. 2017; 91: 1-17
- Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: a review.J Adv Res. 2017; 8: 149-159
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.Cancer. 2003; 97: 3036-3043
- EASL recommendations on treatment of hepatitis C 2016.J Hepatol. 2017; 66: 153-194
- EASL-ALEH clinical practice guidelines: noninvasive tests for evaluation of liver disease severity and prognosis.J Hepatol. 2015; 63: 237-264
- Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.J Hepatol. 2012; 57: 1177-1185
- Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy.Gut Liver. 2017; 11: 870-877
- The oncologic burden of hepatitis C virus infection: a clinical perspective.CA Cancer J Clin. 2017; 67: 411-431
- Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization.Korean J Hepatol. 2011; 17: 299-306
- Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012; 9: 156-166
- Hepatitis C in the rituximab era.Blood. 2010; 116: 5081-5082
- Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.Cancer. 1998; 83: 1224-1230
- Efficacy and safety of new direct antiviral agents in HCV infected patients with diffuse large B cell non-Hodgkin lymphoma.Hepatology. 2018; 67: 48-55
- Treatment of acute hepatitis C with ledipasvir and sofosbuvir in patients with hematological malignancies allows early re-start of chemotherapy.Clin Gastroenterol Hepatol. 2018; 16: 977-978
- Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.Aliment Pharmacol Ther. 2016; 44: 1235-1241
- Hepatitis C-associated B-cell non Hodgkin lymphomas. Epidemiology, molecular signature and clinical management.J Hepatol. 2013; 59: 169-177
- Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.N Engl J Med. 2002; 347: 89-94
- Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.Blood. 2015; 125: 2446-2447
- Interferon- free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.Blood. 2016; 1128: 2527-2532
- Remission of follicular lymphoma after treatment for hepatitis C virus infection.N Engl J Med. 2016; 375: 1699-1701
- Hepatitis C virus screening in patients with cancer receiving chemotherapy.J Oncol Pract. 2014; 10: e167-e174
- Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.BMC Cancer. 2015; 15: 999
- Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.Hepatology. 2015; 62: 932-954
- Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study.Hepatology. 2018; 67: 36-47
- Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?.Clin Gastroenterol Hepatol. 2014; 12: 1051-1054
- Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know?.Ther Adv Hematol. 2016; 7: 94-107
- Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma.World J Hepatol. 2011; 3: 278-284
- Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.Hepatology. 2017; 66: 1341-1343
- Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.Am J Med. 2007; 120: 1034-1041
- Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey.Leuk Lymphoma. 2014; 55: 2564-2571
- Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.Haematologica. 2014; 99: 489-496
- Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation.Blood. 2002; 100: 17-21
- High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.Blood. 2009; 114: 1306-1313
- Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.Blood. 2010; 116: 5119-5125
- Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.Am J Hematol. 2008; 83: 59-62
- HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens.Dig Liver Dis. 2011; 43: 139-142
- Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of fatal cases.Am J Surg Pathol. 2015; 39: 212-220
- From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?.Expert Rev Hematol. 2017; 10: 719-772
- ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Ann Oncol. 2013; 24: 857-877
- Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma).Clin Lymphoma Myeloma Leuk. 2015; 15: 75-85
- Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).Lancet Infect Dis. 2016; 16: 606-617
NCCN guidelines, version 1, 2014: non-Hodgkin’s lymphomas (2017 update). Available at: http://www.nccn.org/professionals/default.aspx.
- Antiviral therapies for managing viral hepatitis in lymphoma patients.Expert Opin Pharmacother. 2017; 18: 363-376
- Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation task force recommendations.Biol Blood Marrow Transplant. 2015; 21: 1870-1882
- ESMO handbook on cancer treatment in special clinical situations.ESMO Publishing Working Group, 2013
- International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates.Transplantation. 2017; 101: 945-955
- Common issues in the management of patients in the waiting list and after liver transplantation.Dig Liver Dis. 2017; 49: 241-253
- The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.Liver Transpl. 2003; 9: S28-S34
- Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.J Hepatol. 2013; 58: 1028-1041
- The association between hepatitis C infection and survival after orthotopic liver transplantation.Gastroenterology. 2002; 122: 889-896
- International liver transplantation society consensus statement on hepatitis C management in liver transplant recipients.Transplantation. 2017; 101: 956-967
- Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.J Hepatol. 2017; 67: 1168-1176
- Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.J Viral Hepat. 2017; 24: 823-831
- Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis.Gastroenterology. 2017; 153: 1273-1283
- Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study.J Hepatol. 2016; 65: 524-531
- Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.Gastroenterology. 2015; 149: 649-659
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol. 2016; 64: 1224-1231
- Systematic review: interferon-free regimens for patients with HCV-related child C cirrhosis.Aliment Pharmacol Ther. 2017; 45: 1193-1200
- Before or after transplantation? A review of the cost effectiveness of treating waitlisted patients with Hepatitis C.Transplantation. 2017; 101: 933-937
- EASL guidelines on hepatitis C.J Hepatol. 2018; 69: 461-511
- Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens.Gastroenterology. 2016; 151: 70-86
- ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.J Hepatol. 2017; 67: 585-602
- Direct-acting antiviral therapy and improvement in graft survival of hepatitis C liver transplant recipients.Transplantation. 2017; 101: e349
- Calcineurin inhibitors in liver transplantation — still champions or threatened by serious competitors?.Liver Int. 2013; 33: 656-665
- Current challenges and future directions for liver transplantation.Liver Int. 2017; 37: 317-327
- Pros and cons: usage of organs from donors infected with hepatitis C virus — revision in the direct-acting antiviral era.J Hepatol. 2016; 64: 226-231
- Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.J Am Med Assoc. 2006; 296: 1843-1850
- Hepatitis C virus infection and lung transplantation: a survey of practices.J Hear Lung Transplant. 1999; 18: 456-459
- Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival.Gastroenterology. 2000; 119: 1064-1074
- HBV and HCV infections in heart transplant recipients.J Hear Lung Transpl. 2001; 20: 718-724
- Hepatitis C status of heart transplant recipients.Clin Transpl. 1998; 12: 5-10
- Serologic responses to hepatitis C virus in solid organ transplant recipients.Transplantation. 1997; 64: 1775-1780
- Hepatitis C in transplant recipients of solid organs, other than liver.Clin Liver Dis. 2006; 10: 901-917
- Influence of preexisting hepatitis C virus antibody positivity in simultaneous pancreas-kidney transplant recipients.Transplantation. 2010; 90: 61-67
- Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients.Transplantation. 2003; 75: 982-986
- The outcome of heart transplantation in hepatitis C-positive recipients.Transpl Proc. 2012; 44: 890-893
- The effect of recipient hepatitis C virus infection on outcomes following heart transplantation.Transplant Proc. 2010; 42: 1784-1787
- Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for Organ Sharing Database).Am J Cardiol. 2016; 118: 132-137
- Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity.J Hear Lung Transplant. 2011; 30: 1266-1274
- Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients.Transplantation. 2011; 91: 1293-1296
- Survival following lung transplantation in not impacted by hepatitis C infection.Am J Transpl. 2016; 16: 2445-2452
- Outcomes after lung transplantation in patients with chronic hepatitis C virus infection.J Heart Lung Transplant. 2007; 26: 466-471
- Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry.Aliment Pharmacol Ther. 2016; 44: 271-278
- Impact of hepatitis C virus status in pancreas transplantation: a case controlled study.Clin Transpl. 2002; 16: 243-251
- The rise of the opioid epidemic and hepatitis C positive organs: a new era in liver transplantation.Hepatology. 2018; 67: 1600-1608
- Trial of transplantation of HCV-infected kidneys into uninfected recipients.N Engl J Med. 2017; 376: 2394-2395
- Rational heart transplant from hepatitis C donor: new antiviral weapons conquer the trojan.J Card Fail. 2017; 23: 765-767
- Epidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in France.Liver Int. 2017; 37: 820-826
- Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data.Transplant Proc. 2008; 40: 909-914
- The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment.Clin J Am Soc Nephrol. 2007; 2: 563-575
- Hepatitis C virus infection and the dialysis patient.Semin Dial. 2007; 20: 416-422
- Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.Hepatology. 2015; 61: 1495-1502
- Hepatitis C cure with antiviral therapy-benefits beyond the liver.Antivir Ther. 2016; 21: 1-8
- Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial.Ann Intern Med. 2017; 166: 109-117
- Transplantation of kidneys from HCV-positive donors: how to best use a scarce resource.J Am Soc Nephrol. 2017; 28: 3139-3141
- Arthritis in patients with chronic hepatitis C virus infection.J Rheumatol. 1999; 26: 420-424
- Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis.J Rheumatol. 1999; 26: 370-372
- Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy.Dig Liver Dis. 2012; 44: 49-54
- Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents.Rheum Dis Clin North Am. 2017; 43: 123-132
- Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems.Dig Liver Dis. 2014; 46: 777-782
- Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol. 2013; 11: 1655-1660
- Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.Rheumatology (Oxford). 2011; 50: 1700-1711
- Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.J Infect. 2017; 74: 433-441
- Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis. A retrospective study in 80 patients with follow-up of 60 months.Transplantation. 1991; 52: 645-650
Article info
Publication history
Published online: October 01, 2018
Accepted:
September 18,
2018
Received:
May 22,
2018
Identification
Copyright
© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
